Stem Cell Transplantation for Newly Diagnosed M/M

 

PrecisCa
Avatar

Induction Therapy for Patients With High-Risk NDMM: When to Utilize Four-Drug Combinations Upfront?

By PrecisCa FEATURING Ajay Nooka
By PrecisCa FEATURING Ajay Nooka
65 views
September 15, 2022
0 Comments
Login to view comments. Click here to Login
Stem Cell Transplantation for Newly Diagnosed M/M
18:35
Rush University Medical Center

Upfront Autologous Transplant in Multiple Myeloma

Feat. C. Hofmeister
34:28
2022 Community Oncology Conference

Treatment Conundrums in Myeloma

Feat. S. Giralt
04:46
ASCO 2022 Conference Coverage

ASCO 2022 on a Post Hoc Analysis of Sustained MRD Negativity From th…

Feat. C. Rodriguez
05:24
Luciano Costa

Dara-KRd, Autologous Transplantation, and MRD Response-Adapted Conso…

07:36
ASCO 2022 Conference Coverage

ASCO 2022 on the Changing Landscape in Post-Transplant Treatment of …

Feat. A. Jakubowiak
08:09
Krina Patel

What Constitutes a Patient That Is Newly Diagnosed With MM as Eligib…

08:41
Parameswaran Hari

The Role of Plerixafor for Stem Cell Mobilization in the Setting of …

05:09
ASCO 2022 Conference Coverage

ASCO 2022 on Myeloma Developing Regimens Using Genomics (MyDRUG) Tri…

Feat. S. Kumar
09:32
Christian Chabannon

Stem Cell Mobilization in MM

24:19
Dana-Farber Cancer Institute

Phase 3 DETERMINATION Trial: RVd ± ASCT & Lenalidomide Maintenan…

Feat. P. Richardson
10:29
Mary Kwok

Moving to Quadruplets in NDMM

05:37
PrecisCa

Induction Therapy for Patients With High-Risk NDMM: When to Utilize …

Feat. A. Nooka
09:01
Mattia D'Agostino

IMS 2022 on Predictors of Unsustained Negativity in MRD(-) Transplan…

13:17
Andrzej Jakubowiak

IMS 2022 ATLAS: A Phase 3 Randomized Trial of Carfilzomib, Lenalidom…

09:09
Douglas W. Sborov

IMS 2022 Final Analysis of the GRIFFIN Trial: Daratumumab + Lenalido…

15:46
SOHO 2022 Tenth Annual Meeting

SOHO 2022: MM Frontline Therapy for Transplant-Eligible/Ineligible P…

Feat. P. Voorhees
07:11
SOHO 2022 Tenth Annual Meeting

SOHO 2022 MM DEBATE: Auto + Maintenance Should Remain SoC in MM

Feat. A. Krishnan